The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2020
year mood +0.16 · -0.30 to +0.50 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan Feb Mar -0.30 Apr May Jun Jul Aug Sep Oct Nov Dec +0.50
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.20+0.10-0.30-0.10+0.10+0.20+0.30+0.30+0.20+0.30+0.06+0.50

COVID crashed everything in March (elective procedures cancelled, hospitals and devices devastated), but then it became my industry's finest hour: insurers reaped windfalls from deferred claims and vaccine makers raced to blockbuster status…

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 2020
Nov
Pfizer-BioNTech Vaccine 90% Effective, Sparking Market Rotation cnbc.com →

Pfizer and BioNTech announced their COVID-19 vaccine is over 90% effective, driving a historic market rotation into value stocks and boosting sectors like travel, hospitality, and banks. The Dow surged 834 points while tech stocks sold off, signaling investor optimism about economic reopening and a shift away from pandemic winners like Zoom and Amazon.

Nov
Moderna vaccine 94.5% effective, boosting reopening trade cnbc.com →

Moderna announced its COVID-19 vaccine is 94.5% effective based on interim phase three trial data, with no significant safety concerns, spurring a 12% jump in shares. The results, following Pfizer's similar success, validate mRNA vaccine technology and support expectations of broad distribution by mid-2021, with major implications for economic reopening and global vaccine equity.